Hsbc Holdings PLC Invests $1.03 Million in Replimune Group, Inc. $REPL

Key Points

• HSBC Holdings initiated a position in Replimune Group by purchasing 92,154 shares worth approximately $1.03 million, representing about 0.11% of the company. Institutional investors collectively own 92.53% of Replimune’s stock.
• Replimune shares rose 2.4% to $15.67, near their 52-week high of $16.15. The company reported a quarterly loss of $0.72 per share, missing analyst expectations of a $0.69 loss.
• Analyst sentiment is mixed but leans positive, with a consensus rating of “Moderate Buy” and an average price target of $12.00. Recent actions included upgrades from Piper Sandler, JPMorgan, and BMO Capital Markets, while insiders have sold shares primarily to cover tax obligations.

Hsbc Holdings PLC bought a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 92,154 shares of the company's stock, valued at approximately $1,035,000. Hsbc Holdings PLC owned approximately 0.11% of Replimune Group as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of REPL. Legal & General Group Plc acquired a new position in Replimune Group during the second quarter valued at approximately $85,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Replimune Group in the second quarter worth $231,000. Ieq Capital LLC acquired a new stake in shares of Replimune Group in the second quarter worth $908,000. Allworth Financial LP purchased a new position in shares of Replimune Group in the 2nd quarter valued at $62,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Replimune Group during the 2nd quarter valued at $119,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Trading Up 2.4%

Shares of REPL opened at $15.67 on Wednesday. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $16.15. The stock has a 50-day moving average price of $12.00 and a 200 day moving average price of $8.45. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The company has a market capitalization of $1.47 billion, a P/E ratio of -4.97 and a beta of 0.88.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Sell-side analysts forecast that Replimune Group, Inc. will post -2.81 EPS for the current fiscal year.

Insider Activity at Replimune Group

In related news, CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the sale, the chief accounting officer owned 99,425 shares in the company, valued at approximately $1,289,542.25. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the sale, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. This represents a 4.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,124 shares of company stock worth $1,038,364 in the last ninety days. 5.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on REPL shares. Piper Sandler raised shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on Replimune Group from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 26th. Weiss Ratings downgraded Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. BMO Capital Markets upgraded Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 target price for the company in a research note on Tuesday, June 30th. Finally, Wall Street Zen upgraded Replimune Group from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $12.00.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source